146277-47-6

Basic information

• Product Name: (S)-2-AMINO-3-(2,4,6-TRIMETHYL-PHENYL)-PROPIONIC ACID
• Synonyms: (S)-2-AMINO-3-(2,4,6-TRIMETHYL-PHENYL)-PROPIONIC ACID;L-2,4,6-trimethylpeh;Phe(2,4,6-triMe)-OH
• CAS NO: 146277-47-6
• Molecular Formula: C₁₂H₁₇NO₂
• Molecular Weight: 207.27
• Mol File: 146277-47-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: (S)-2-AMINO-3-(2,4,6-TRIMETHYL-PHENYL)-PROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-AMINO-3-(2,4,6-TRIMETHYL-PHENYL)-PROPIONIC ACID(146277-47-6)
• EPA Substance Registry System: (S)-2-AMINO-3-(2,4,6-TRIMETHYL-PHENYL)-PROPIONIC ACID(146277-47-6)

Safety Data

• Hazardous Substances Data: 146277-47-6(Hazardous Substances Data)

Usage

Uses

Used in Biochemical Research:
(S)-2-AMINO-3-(2,4,6-TRIMETHYL-PHENYL)-PROPIONIC ACID is used as a research compound for various biochemical studies. Its unique structure and properties make it a valuable tool in understanding the interactions and mechanisms of amino acids and their derivatives in biological systems. (S)-2-AMINO-3-(2,4,6-TRIMETHYL-PHENYL)-PROPIONIC ACID can be employed in the development of new drugs, the study of metabolic pathways, and the investigation of enzyme activities.

Downstream Products

• 943726-84-9 N^α-tert-butyloxycarbonyl-2',6'-dimethyl-L-tyrosyl-L-prolyl-2',4',6'-trimethyl-L-phenylalanyl-L-phenylalanylamide 
• 943726-83-8 N^α-tert-butyloxycarbonyl-L-tyrosyl-L-prolyl-2',4',6'-trimethyl-L-phenylalanyl-L-phenylalanylamide 
• 943726-73-6 N^α-tert-butyloxycarbonyl-2',4',6'-trimethyl-L-phenylalanyl-L-phenylalanylamide 
• 82317-87-1 N^α-tert-butyloxycarbonyl-2',4',6'-trimethyl-L-phenylalanine 

Relevant articles and documents

METHOD FOR THE STEREOSELECTIVE PREPARATION OF AMINO ACID DERIVATIVES

The invention relates to a process for the stereoselective preparation of amino acid derivatives, comprising a hydrogenation reaction of the compound of formula (III), alternatively its enantiomer, wherein R is (C1-C8)-alkyl; followe

A unified approach to mesityl amino acids based on Sharpless dihydroxylation

Enantioselective syntheses of two mesityl (2,4,6-trimethylphenyl) amino acids are described. Starting from ethyl 3-mesityl-2-propenoate both enantiomeric dihydroxy esters 5 were prepared in excellent yield and enantiomeric purity (>99% ee) by Sharpless di

Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists

Nonapeptide and decapeptide analogs of LHRH which have the formula: STR1 and the pharmaceutically acceptable salts thereof, wherein: X is a D-alanyl residue wherein one hydrogen on C-3 is replaced by:(a) a carbocyclic aryl-containing radical selected from the group consisting of phenyl substituted with three or more straight chain lower alkyl groups, naphthyl, anthryl, fluorenyl, phenanthryl, biphenylyl and benzhydryl; or(b) a saturated carbocyclic radical selected from the group consisting of cyclohexyl substituted with three or more straight chain lower alkyl groups, perhydronaphthyl, perhydrobiphenylyl, perhydro-2,2-diphenylmethyl, and adamantyl; or(c) a heterocyclic aryl containing radical selected from the group consisting of radicals represented by the following structural formulas: STR2 wherein A"" and A'' are independently selected from the group consisting of hydrogen, lower alkyl, chlorine, and bromine, and G is selected from the group consisting of oxygen, nitrogen, and sulfur;A is an aminoacyl residue selected from the group consisting of L-pyroglutamyl, D-pyroglutamyl, N-acyl-L-prolyl, N-acyl-D-prolyl, N-acyl-D-tryptophanyl, N-acyl-D-phenylalanyl, N-acyl-D-p-halophenylalanyl, and N-acyl-X wherein X is as defined previously;B is an amino acyl residue selected from the group consisting of D-phenylalanyl, D-p-halophenylalanyl, 2,2-diphenylglycyl, and X wherein X is as defined previously;C is an amino acyl residue selected from the group consisting of L-tryptophanyl, D-tryptophanyl, D-phenylalanyl and X wherein X is as defined above;E is glycinamide or --NH--R 1, wherein R 1 is lower alkyl, cycloalkyl, fluoro lower alkyl or STR3 wherein R 2 is hydrogen or lower alkyl; are disclosed. These compounds are LHRH antagonists.